The estimated Net Worth of Katherine J Klein is at least $5.06 Milion dollars as of 8 March 2024. Katherine Klein owns over 9,791 units of United Therapeutics Corp stock worth over $4,649,678 and over the last 10 years he sold UTHR stock worth over $0. In addition, he makes $411,945 as Independent Director at United Therapeutics Corp.
Katherine has made over 4 trades of the United Therapeutics Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 9,791 units of UTHR stock worth $1,211,636 on 8 March 2024.
The largest trade he's ever made was exercising 9,791 units of United Therapeutics Corp stock on 8 March 2024 worth over $1,211,636. On average, Katherine trades about 1,033 units every 76 days since 2014. As of 8 March 2024 he still owns at least 13,431 units of United Therapeutics Corp stock.
You can see the complete history of Katherine Klein stock trades at the bottom of the page.
Prof. Katherine J. Klein Ph.D. serves as Independent Director of the Company. Professor Klein has served as the Vice-Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School's Edward H. Bowman Professor of Management since 2005. She also served as Professor of Management of The Wharton School from 2004 to 2005. Prior to joining Wharton, Professor Klein was on the faculty of the University of Maryland and a visiting professor at the Stanford Graduate School of Business. She received her B.A. from Yale University, and her Ph.D. in Community Psychology from the University of Texas at Austin. An award-winning organizational psychologist, Professor Klein has conducted extensive field research regarding a range of topics including team leadership, climate, conflict, social networks and effectiveness; organizational change and technology implementation; employee diversity; and employee responses to stock ownership. She has taught executive education and consulted with and studied a variety of for-profit and non-profit organizations including Charles Schwab, Rohm and Haas, North American Scientific, Medtronic, The Baltimore Shock Trauma Center, Penn Vet, the U.S. Census Bureau, and the Korean Management Association. Her research has been published in numerous top journals including Administrative Science Quarterly, Journal of Applied Psychology, the Academy of Management Journal, and the Academy of Management Review. She is also a former associate editor of the Journal of Applied Psychology and Administrative Science Quarterly. Professor Klein is a Fellow of the Academy of Management, the Society for Industrial and Organizational Psychology, the American Psychological Association, and the Association for Psychological Science. She has served as a United Therapeutics director since 2014.
As the Independent Director of United Therapeutics Corp, the total compensation of Katherine Klein at United Therapeutics Corp is $411,945. There are 17 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.
Katherine Klein is 63, he's been the Independent Director of United Therapeutics Corp since 2014. There are 8 older and 12 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.
Katherine's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.
Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli a Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: